|
| Search for Cases |
|
Case Details |
|
Case Code: FINC137
|
| Case Length: 7 Pages |
| Period: 2008 - 2017 |
| Pub Date: 2018 |
| Teaching Note: Available |
| Price:Rs.200 |
| Organization : Lupin Limited |
Industry : Pharmaceuticals
|
| Countries : India |
| Themes: Risk Return Analysis in Corporate Finance |
|
|
|
|
Lupin Stock: Risk and Return |
|
|
|
|
| <<Previous Page |
INTRODUCTION |
| |
| The stock price of Lupin Limited (Lupin) hit a 52-week low of INR (Rs.) 846.20, on November 7, 2017, when the Indian pharma major informed the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) that it had received a warning letter from the US Food and Drug Administration (USFDA) (WL) (Refer to Exhibit 1 for the daily stock price data for the month November 2017 and to Graph 1 for a graphical depiction of the stock prices around the news date, and to Exhibit 2 for the monthly stock price data for the year November 2016 to November 2017). Following the steep decline in the stock price, the company's market valuation eroded by Rs 78.66 billion...
|
| |
 |
| or |
 |
| or |
PayPal (5 USD)
|
|
|
| |
|
| |
| ABOUT LUPIN - Next Page>> |
| |
|
| |
|
|
|
